Company news

Aclaris Therapeutics, Inc. news in 2023

Aclaris Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Aclaris Therapeutics Provides Corporate Update

December 18, 2023

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

December 4, 2023

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

November 12, 2023

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

November 5, 2023

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

October 2, 2023

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

September 19, 2023

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

September 17, 2023

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

August 6, 2023

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

June 12, 2023

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

June 1, 2023

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

May 7, 2023

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

May 1, 2023

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

March 26, 2023

Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa

March 5, 2023

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

February 22, 2023

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

February 8, 2023

Aclaris Therapeutics Provides 2023 Outlook

January 5, 2023

Calls in 2023

Decks in 2023